Ossiam Acquires 1,105 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ossiam raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 28.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,028 shares of the company's stock after purchasing an additional 1,105 shares during the quarter. Ossiam's holdings in IDEXX Laboratories were worth $2,079,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. United Capital Financial Advisors LLC increased its position in IDEXX Laboratories by 0.9% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after purchasing an additional 22 shares during the period. Cranbrook Wealth Management LLC boosted its stake in shares of IDEXX Laboratories by 7.0% in the 4th quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after purchasing an additional 25 shares during the last quarter. Gabelli Funds LLC grew its position in shares of IDEXX Laboratories by 5.3% during the 4th quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after buying an additional 25 shares during the period. Perigon Wealth Management LLC raised its stake in shares of IDEXX Laboratories by 1.8% during the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after buying an additional 26 shares during the last quarter. Finally, Summit Trail Advisors LLC lifted its holdings in IDEXX Laboratories by 3.3% in the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after buying an additional 26 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Analyst Ratings Changes

IDXX has been the subject of several recent research reports. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a report on Monday, April 14th. Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Finally, StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 12th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus target price of $523.75.

Insider Activity

In related news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Down 0.8 %

IDXX traded down $3.54 during trading on Friday, reaching $437.44. The company had a trading volume of 939,200 shares, compared to its average volume of 631,554. The company has a market cap of $35.45 billion, a P/E ratio of 41.00, a PEG ratio of 3.41 and a beta of 1.50. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $548.88. The business's fifty day moving average price is $420.16 and its 200 day moving average price is $429.68.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.